sp_news grid="3"

Q2Pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR)
November 4, 2018

My News 3

The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33...
Read More
Q2Pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR)
November 4, 2018

My News 2

The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33...
Read More
November 4, 2018

Case Western Reserve Embarks on Innovative Path to Treat Infections of Drug-Resistant Superbugs such as MRSA without Antibiotics

School of Medicine’s biochemistry department team, in partnership with Q2 Pharma, to develop antivirulence agents that disarm bacteria of deadly...
Read More
sp_news
Q2Pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR)

4

Nov 18

My News 3

The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33...
Read More
Q2Pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR)

4

Nov 18

My News 2

The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33...
Read More

4

Nov 18

Case Western Reserve Embarks on Innovative Path to Treat Infections of Drug-Resistant Superbugs such as MRSA without Antibiotics

School of Medicine’s biochemistry department team, in partnership with Q2 Pharma, to develop antivirulence agents that disarm bacteria of deadly...
Read More
Q2Pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR)